PRKDC and melanoma: Several inhibitors of DNA-PK have recently been developed [69,70], and using a dual inhibitor of mTOR kinase and DNA-PK called CC-115, currently being studied in phase I/II clinical trials, has been shown to radiosensitize melanoma cell lines [71].